Literature DB >> 10679651

The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.

S F Lax1, B Kendall, H Tashiro, R J Slebos, L Hedrick.   

Abstract

BACKGROUND: The two most common types of uterine endometrial carcinoma, endometrioid (UEC) and serous (USC), differ in their histopathologic appearance and biologic behavior. Recent studies suggest that these differences may be associated with distinct molecular genetic alterations.
METHODS: In the current study, the authors compared the frequencies of K-ras and p53 mutations and microsatellite instability (MI) between UEC and USC by analyzing all 3 molecular genetic changes in one set of tumors. Furthermore, the distribution of these molecular genetic alterations was determined among UECs of different histopathologic grade. The authors analyzed 58 UECs with known MI status for K-ras and p53 mutations. The K-ras and p53 genes were analyzed in 45 and 6 cases of USC, respectively. These results were combined with previous data on p53 mutations (21 cases) and MI (34 cases) in USC.
RESULTS: MI was present in 16 of 57 UECs (28%) but in none of 34 USCs. p53 mutations were found in 7 of 42 UECs (17%) and 25 of 27 USCs (93%) by direct sequencing of exons 5-8. UECs and USCs with p53 mutations showed strong immunoreactivity for p53 in about 85% of the cases, whereas about 15% of the cases were immunonegative. K-ras mutations at codon 12 were found in 15 of 58 UECs (26%) and in only 1 of 45 USC (2%) by dot blot oligohybridization after polymerase chain reaction amplification of exon 1. Notably, the frequency of both K-ras and p53 mutations and MI was significantly different between UEC and USC (P < 0.001). In UECs, MI and K-ras mutations occurred in low grade as well as in high grade tumors, whereas p53 mutations were present almost exclusively in high grade tumors.
CONCLUSIONS: The results of this study suggest that different molecular genetic pathways are involved in the pathogenesis of UEC and USC and that low grade UEC may progress to high grade UEC. These findings support the hypothesis that UEC and USC are separate entities and suggest that different molecular genetic alterations may be responsible for their distinct morphology and biologic behavior. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679651

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  102 in total

1.  A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model.

Authors:  Zhihe Liu; Guanghua Wan; Christopher Heaphy; Marco Bisoffi; Jeffrey K Griffith; Chien-An A Hu
Journal:  Mol Cell Biochem       Date:  2006-11-21       Impact factor: 3.396

2.  Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization.

Authors:  Wanja Kildal; Francesca Micci; Bjørn Risberg; Vera M Abeler; Gunnar B Kristensen; Sverre Heim; Håvard E Danielsen
Journal:  Mol Oncol       Date:  2011-10-20       Impact factor: 6.603

3.  Establishment and characterization of a human cell line derived from a uterine papillary serous carcinoma with wild-type p53 function.

Authors:  Hisashi Hashimoto; Atsumi Kojima; Tamotsu Sudo; Noriyoshi Ohki; Satoshi Yamaguchi; Yoshiki Mikami; Masaharu Ito; Ryuichiro Nishimura
Journal:  Hum Cell       Date:  2008-08       Impact factor: 4.174

4.  The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.

Authors:  Larissa A Meyer; Brian M Slomovitz; Bojana Djordjevic; Shannon N Westin; David A Iglesias; Mark F Munsell; Yunyun Jiang; Rosemarie Schmandt; Russell R Broaddus; Robert L Coleman; John M Galbincea; Karen H Lu
Journal:  Int J Gynecol Cancer       Date:  2014-05       Impact factor: 3.437

5.  Identification of potential serum markers for endometrial cancer using protein expression profiling.

Authors:  Masashi Takano; Yoshihiro Kikuchi; Takayoshi Asakawa; Tomoko Goto; Tsunekazu Kita; Kazuya Kudoh; Junzo Kigawa; Noriaki Sakuragi; Masaru Sakamoto; Toru Sugiyama; Nobuo Yaegashi; Hiroshi Tsuda; Hiroshi Seto; Mieko Shiwa
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

Review 6.  My approach to the interpretation of endometrial biopsies and curettings.

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

Review 7.  Non-Coding RNAs in Endometrial Physiopathology.

Authors:  Alessandro La Ferlita; Rosalia Battaglia; Francesca Andronico; Salvatore Caruso; Antonio Cianci; Michele Purrello; Cinzia Di Pietro
Journal:  Int J Mol Sci       Date:  2018-07-20       Impact factor: 5.923

Review 8.  Origin of ovarian cancer: molecular profiling.

Authors:  Dilip Kumar Dutta; Indranil Dutta
Journal:  J Obstet Gynaecol India       Date:  2013-06-21

9.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

Review 10.  Promising novel therapies for the treatment of endometrial cancer.

Authors:  Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.